Zim Laboratories Limited — Important, 04-08-2025: Granting/withdrawal/surrender/cancellation/suspension of key licenses/ regulatory approvals

ZIM Laboratories' Australian subsidiary, ZIMTAS, has secured Marketing Authorization from the Therapeutic Goods Administration (TGA) for "Tamsulosin Hydrochloride and Dutasteride Capsules." This combination drug treats moderate to severe symptoms of benign prostatic hyperplasia (BPH), offering improved patient convenience through its fixed-dose format. This approval marks ZIM's second authorization in Australia, strategically enhancing its presence in regulated markets. It paves the way for commercial launch and supports future global regulatory filings, significantly strengthening ZIM's urology product line.